6:02 PM
 | 
Nov 14, 2013
 |  BC Extra  |  Top Story

Epizyme slides on Phase I data for EPZ-5676

Epizyme Inc. (NASDAQ:EPZM) fell $11.77 (37%) to $19.94 on Thursday after reporting data from 16 patients in the first four cohorts of an open-label Phase I trial of EPZ-5676 to treat adults with heavily pre-treated advanced hematological malignancies -- the first human data from the company. Epizyme said treatment effects "consistent with the genetically defined therapeutic mechanism...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >